Actualités

A 7% dividend yield will grab your attention, but be sure to read the fine print.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July

Pfizer (PFE) concluded the recent trading session at $23.72, signifying a -2.47% move from its prior day's close.

Before the share price caught on, the drugmaker was dealing with a problem most companies only dream of, and it was the clearest sign a surge was building.

ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.

Pfizer's IBRANCE has received new FDA approval as the first CDK4/6 inhibitor maintenance therapy for HR+, HER2+ metastatic breast cancer after induction treatment. The approval covers use of IBRANCE in combination with trastuzumab and endocrine therapy for patients with this subtype of breast cancer. The decision is based on results from the Phase 3 PATINA trial. For investors watching Pfizer (NYSE:PFE), this approval adds a fresh clinical milestone to a stock that has faced pressure in...

Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday. With second-quarter earnings starting this week, and with all of the major indices trading at or near all-time highs, you ... Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More

Pfizer Inc. (NYSE:PFE) is one of the best dividend stocks to buy, according to hedge funds. On June 24, the US Food and Drug Administration approved the use of Pfizer Inc. (NYSE:PFE)’s Ibrance in combination with trastuzumab as a maintenance option for patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer after induction treatment. […]

Could this be the secret to Pfizer's rebound strategy?

(Bloomberg) -- President Donald Trump made more than 21,000 securities trades in his first year back in office, often in intense bursts tied to market events he created.Most Read from BloombergExxon to Change Name for First Time in Decades After RedomicileMeta Is Planning a Cloud Business to Sell AI Computing PowerGermany Rejects Trump’s Demands for NATO Loyalty to WashingtonRussia Indicates Ukraine Fired Long-Range Ballistic MissileKrafton Agrees to Pay ‘Subnautica 2’ Bonuses as Developer’s CEO

The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting game for investors.

Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.

Five of the biggest names in American pharma just got a deadline from Washington. The House Select Committee on China sent letters this week to Merck (MRK), AbbVie (ABBV), Eli Lilly (LLY), Pfizer (PFE), and Bristol Myers Squibb (BMY), Reuters reported. Lawmakers want each company to explain ...

Passive income is the paycheck that arrives whether you show up or not. Wages depend on a functioning employer, a healthy economy, and the continued willingness of both to keep the seat warm. Dividend income depends on a company writing a check every 90 days, and for a handful of blue chips, that check has ... $500 a Month in These Stocks Will Generate $6,700 in Passive Annual Income

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

Pfizer stock is trading in a range where recent returns have been weak over three years, yet the broader valuation checks still lean cheap and suggest the current share price may not fully reflect the company’s fundamentals. Over the past 3 years, Pfizer has delivered a total return that is down about 21%, which shows how much sentiment has cooled since its pandemic peak. The push into oncology and obesity treatments, including recent IBRANCE progress and weight loss drug development, can...

Pfizer (PFE) closed at $24.08 in the latest trading session, marking a -1.19% move from the prior day.

Nike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea

Nike stock (NKE) is moving lower in Tuesday's extended-hours trading after reporting mixed results for the sportswear brand's fiscal fourth quarter: while earnings topped estimates, revenue declined 1.1% year-over-year. Morningstar senior equity analyst David Swartz discusses what he was expecting from the earnings release and how Nike's performance is lining up with CEO Elliott Hill's turnaround strategy.

The healthcare giant is making waves, but its true value for investors lies in how little it moves with the market.

Volatility can lower the cost of entry into businesses that throw off real cash, even as investors recognize that a low share price alone is no guarantee of a bargain. Heading into the back half of 2026, three blue-chip names trading well below the $45 mark stand out for the same reason: predictable cash flows, ... 3 Dirt-Cheap Stocks Under $45 Built to Outperform in a Volatile Market

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country’s military capabilities, according to a...

I keep buying Pfizer (NYSE:PFE) every time my brokerage cash builds up, and I am not slowing down. The market is treating this company like a value trap because COVID revenue is rolling off. I am treating it like a cash machine that just bought itself three extra years of patent life on one of ... Wall Street Walked Away From This Powerhouse Stock, But I Am Buying It on Repeat

CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.

CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.